Beam Therapeutics Revenue and Competitors

Boston, MA USA

Location

$689M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Beam Therapeutics's estimated annual revenue is currently $67.7M per year.(i)
  • Beam Therapeutics received $135.0M in venture funding in March 2019.
  • Beam Therapeutics's estimated revenue per employee is $123,379
  • Beam Therapeutics's total funding is $689M.
  • Beam Therapeutics's current valuation is $4.6B. (January 2022)

Employee Data

  • Beam Therapeutics has 549 Employees.(i)
  • Beam Therapeutics grew their employee count by 1% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.2M10%N/AN/A
#3
$4.2M2735%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$1.4M929%N/AN/A
#6
$235M255-31%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.3M340%N/AN/A
#10
$1.9M12-8%N/AN/A
Add Company

Beam Therapeutics is developing precision genetic medicines for serious diseases. Co-founded by scientific pioneers known for advancing CRISPR gene editing, were the first company to pursue development of new therapies using CRISPR base editing technology. We aim to use these technologies to generate a broad pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, or modulate the expression or function of disease-causing genes. WHO WE ARE Beam is creating precision genetic medicines through base editing WHY WE DO IT Our dream is to provide life-long cures for patients suffering from serious diseases WHO WE ARE AND HOW WE WORK TOGETHER The Beam Team: A community of fearless innovators Rigorous and honest in our research Listening with open minds Committed to each other

keywords:N/A

$689M

Total Funding

549

Number of Employees

$67.7M

Revenue (est)

1%

Employee Growth %

$4.6B

Valuation

N/A

Accelerator

Beam Therapeutics News

2022-04-19 - Beam Therapeutics Inc. (NASDAQ:BEAM) Receives ...

Beam Therapeutics Inc, a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United...

2022-04-17 - Beam Therapeutics Worth Watching Because Of Pfizer Interest?

Pfizer's 4 year partnership with Beam Therapeutics on developing treatments for 3 rare genetic diseases involves $300 million upfront to speed...

2022-04-06 - Beam Therapeutics: Getting More And More Interesting

Beam Therapeutics (NASDAQ:BEAM) is a preclinical stage gene editing company which has a $3.7bn valuation because its founder happens to be...

2020-02-06 - Beam Therapeutics raises $180 million in IPO

Beam Therapeutics (BEAM), a Cambridge, Mass., genome-editing startup, raised $180 million in an initial public offering Wednesday after increasing the number of shares it offered to investors by 48 percent. Unlock this article by subscribing to STAT+ and enjoy your first 30 days free! GET START ...

2019-09-30 - Gene editing company Beam Therapeutics aims for $100M IPO

The company declined to comment because it is in a quiet period in connection with the filing. Beam’s last major financing was a $135 million Series B funding round that it raised in March. It launched in May of last year with an $87 million Series A round after operating in stealth mode for a ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$85.7M55333%N/A
#2
$101M55712%N/A
#3
$173.3M55718%$86.9M
#4
$154.6M56213%N/A
#5
$73.4M56746%$2B

Beam Therapeutics Funding

DateAmountRoundLead InvestorsReference
2018-05-15$87.0MAF-Prime Capital PartnersArticle
2019-03-07$135.0MBMulitepleArticle